Bloomberg Law
Aug. 7, 2020, 12:38 PM

Controversial Alzheimer’s Drug Takes Step Toward FDA Approval

Timothy Annett
Timothy Annett
Bloomberg News

Biogen Inc.’s experimental Alzheimer’s disease treatment aducanumab was granted priority review status by U.S. regulators, a move that could hasten the drug’s arrival on the market.

The company said in a statement Friday that the Food and Drug Administration had granted its application with an action date of March 7, though it said the agency could act earlier under an expedited review.

Shares of the Cambridge, Massachusetts-based biotechnology company climbed by 12% in premarket trading on Friday.

The priority review had been sought by Biogen and its Japan-based partner Eisai Co. when the companies submitted their application for approval ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.